Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
← catalyst calendarSponsored by MBX Biosciences (industry) · MBX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-26 | actual | When the study began enrolling |
| Primary completion | 2026-04-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-01 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Postbariatric Hypoglycemia
Intervention
- Drug: MBX 1416 (INN imapextide)
Primary outcome
what the primary-completion date above is the date OFChanges from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.
measured The duration of the study will be approximately 67 days from screening to end of study (EoS) for any given participant
Permalink · MBX's whole pipeline · Catalyst calendar · Every registered study · What changed